Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	110735
Country	United Kingdom

Received	2025-06-13 05:10
Peer-Review Started	2025-06-13 05:11
To Make the First Decision
Return for Revision	2025-06-18 02:21
Revised	2025-06-29 20:44
Second Decision	2025-10-09 02:32
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-10-09 06:55
Articles in Press	2025-10-09 06:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-10-27 00:14
Publish the Manuscript Online	2025-11-14 00:56

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives
Manuscript Source	Invited Manuscript
All Author List	Mohammed Omar Khalifa Elsayed
Funding Agency and Grant Number
Corresponding Author	Mohammed Omar Khalifa Elsayed, FRCP, MD, Professor, Department of Gastroenterology, South Tees Hospitals NHS Foundation Trust, The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, United Kingdom. dmohammed_omar_76@outlook.com
Key Words	Recurrent hepatocellular carcinoma; Liver resection; Liver transplantation; Locoregional treatments; Current standards
Core Tip	Recurrent hepatocellular carcinoma (HCC) is indeed an increasing concern, especially as the global incidence of chronic liver diseases continues to rise. The management of recurrent HCC remains complex, particularly after liver transplantation or hepatic resection, as there is no universally agreed-upon approach. Several treatment modalities are available as locoregional and systemic therapies, and each comes with its own set of advantages and challenges. As recurrent HCC becomes more prevalent, developing a clear, evidence-based treatment approach will be crucial. Further research and prospective randomized trials are essential to determine the best management strategies, establish guidelines, and improve long-term patient outcomes in this challenging clinical scenario.
Publish Date	2025-11-14 00:56
Citation	<p>Elsayed MOK. Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives. <i>World J Gastrointest Oncol</i> 2025; 17(11): 110735</p>
URL	https://www.wjgnet.com/1948-5204/full/v17/i11/110735.htm
DOI	https://dx.doi.org/10.4251/wjgo.v17.i11.110735

Full Article (PDF)	WJGO-17-110735-with-cover.pdf
Manuscript File	110735_Auto_Edited_073400.docx
Answering Reviewers	110735-answering-reviewers.pdf
Audio Core Tip	110735-audio.m4a
Conflict-of-Interest Disclosure Form	110735-conflict-of-interest-statement.pdf
Copyright License Agreement	110735-copyright-assignment.pdf
Peer-review Report	110735-peer-reviews.pdf
Scientific Misconduct Check	110735-scientific-misconduct-check.png
Scientific Editor Work List	110735-scientific-editor-work-list.pdf
CrossCheck Report	110735-crosscheck-report.pdf